ライフサイエンスコーパス: ART

1 ART in HIV controllers reduces T-cell activation and imp

2 ART significantly reduced HIV-specific T-cell responses

3 ART use was effective in further increasing the proporti

4 ART use was summarized within Global Burden of Disease (

5 Primary outcomes were (1) ART initiation in <=7 days and (2) ART initiation in <=2

6 were (1) ART initiation in <=7 days and (2) ART initiation in <=28 days and retention in care at 8 m

7 reps on longitudinal plasma samples from 50 ART-suppressed individuals in the Reservoir Assay Valida

8 from 47.4% (41.3-53.4) to 76.2% (71.8-80.6), ART use among diagnosed people living with HIV increased

9 There were 90 ART-experienced participants with resistance to both efa

10 After ART was discontinued and as the virus began to spread, a

11 function, and lung injury prior to and after ART initiation in adults with HIV and pulmonary TB.

12 ynamics between these two compartments after ART interruption.

13 ound, and we compare rebound viral RNA after ART discontinuation with near full-length viral DNA from

14 not adversely affect controller status after ART discontinuation.

15 TB or all-cause death within 48 weeks after ART initiation.

16 0.0 (95% CI, 0.0-2.9)/100 person-years after ART in Fiebig I to 15.9 (7.6-29.2) in Fiebig V.

17 Although ART significantly reduced viral loads and increased CD4+

18 Thus, although ART was indispensable for controlling viral replication,

19 rformed nationwide plasma CrAg testing among ART-experienced Ugandan adults with virologic failure (>

20 were randomly assigned to receive either an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60

21 d to receive either an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60 participants complete

22 low adherence (<85%) to both bedaquiline and ART were identified as high-risk for poor outcomes.

23 vices measured adherence for bedaquiline and ART.

24 Inadequate continuity of care and ART coverage present challenges to optimal PMTCT in Guin

25 ic factors, HIV disease characteristics, and ART components and weight change following ART initiatio

26 ccordance with the CAP, Evans', JPS, MDA and ART grading systems, and interobserver concordance was c

27 ART initiation with quarterly monitoring and ART refills through mobile vans; ART initiation at the c

28 lence by 5-year age bins, sex, and year; and ART coverage by age, sex, and year.

29 with viral suppression using antiretroviral [ART] therapy; n = 2 with rebound viremia after stopping

30 participants with HIV (CD4 < 50 cells/uL) at ART initiation to receive either empiric TB treatment or

31 Children <18 years at ART initiation, with sustained viral suppression (VS) (<

32 Attempts to augment ART with therapies that reverse viral latency, paired wi

33 viral suppression compared with clinic-based ART, particularly among men, eliminating disparities in

34 ntage points, enrolment into community-based ART delivery by 25 percentage points, and switching to s

35 ion impact on enrolment into community-based ART delivery.

36 d women (n=150 [75%]) in the community-based ART group.

37 At 12 months, community-based ART increased viral suppression compared with the clinic

38 ith mobile phone software to community-based ART initiation with quarterly monitoring and ART refills

39 When given to all men and women, DTG-based ART could reduce the level of NNRTI PDR from 52.4% (with

40 n resistance levels, whereas using DTG-based ART in all men, or in men and women beyond childbearing

41 PDR would continue to increase if DTG-based ART was restricted to men.

42 everse transcriptase inhibitor (NNRTI)-based ART between January 2007 and June 2016 were included.

43 compared to the continuation of NNRTI-based ART, introducing DTG would lead to a reduction in NNRTI

44 D114N, in an HIV+ patient on tenofovir-based ART with mitochondrial toxicity.

45 cation, income, smoking status, and baseline ART regimen.

46 Before ART initiation, PTCs had higher CD4 T cell counts, lower

47 by clonal expansion of cells infected before ART initiation.IMPORTANCE There are limited data about t

48 Pol is protecting against toxicity caused by ART and individuals with inactivating mutations may be p

49 at were clustered closely, indicating that c-ART partially reversed the gut dysbiosis associated with

50 ggest that complete viral suppression with c-ART could potentially revert microbial dysbiosis observe

51 ted to transition from the standard of care (ART eligibility at CD4 counts of <350 cells/mm3 until Se

52 The mechanisms by which certain ART agents differentially contribute to weight gain are

53 efills (hybrid approach); or standard clinic ART initiation and refills.

54 The most common ART regimens were nucleoside/nucleotide reverse-transcri

55 onsidered the situation in 2018 and compared ART initiation policies of an efavirenz-based regimen in

56 started ART 8 weeks postinfection, continued ART for >7 months, and controlled plasma viremia at <10(

57 Continuing ART with a regimen that includes enfuvirtide post-alloBM

58 cohort (range of 1 to 19 years of continuous ART suppression) showed a median viral load of 0.54 cp/m

59 he absence of drug resistance to the current ART regimen.METHODSSamples were collected from at least

60 We find that every day ART initiation is delayed results in a 39% increase in t

61 offered universal HIV-treatment and same-day ART with a dolutegravir-based regimen at first clinic vi

62 mphasize adherence counseling while delaying ART switch may promote drug resistance and should be rec

63 Artemisinin and its derivatives (ART) are crucial first-line antimalarial drugs that rapi

64 Despite ART, children with HIV have a high incidence of cardiac

65 Three different ART/PrEP prevalence analyses in blood donors were conduc

66 se of bNAbs at 30 h, or a 21-day triple-drug ART regimen at 48 h, are aviremic with almost no virus i

67 bial community upon SIV infection and during ART.

68 hese animals prior to ART initiation, during ART suppression, and following viral rebound, and we com

69 ode mononuclear cells (PBMC and LNMC) during ART suppression.

70 se data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-speci

71 ite for low-level viral transcription during ART.

72 shedding in HIV/HSV-coinfected women during ART may sustain HIV tissue reservoirs via Ag exposure or

73 Entry ART varied by GBD region, with shifts during the trial e

74 ning should be considered in persons failing ART in Uganda with viral loads >=5000 copies/mL.

75 hort Collaboration who initiated their first ART regimen, containing either InSTI (i.e., raltegravir,

76 descences of the infection frequently follow ART monotherapy.

77 d ART components and weight change following ART initiation.

78 safely or to prevent viral rebound following ART cessation.

79 identifying PDR to guide drug selection for ART in a lower-middle income country.

80 chromatography-tandem mass spectrometry for ART.

81 ed with deficits in SIP and motor functions; ART and higher CD4 are associated with better cognitive

82 unction are common on ART, relate to greater ART-mediated CD4 T-cell restoration, and are associated

83 sociated with greater likelihood of hospital ART initiation (p=0.008).

84 a reduction in NNRTI PDR in all scenarios if ART initiators are started on a DTG-based regimen, and t

85 ts to important health benefits of immediate ART initiation; however, the policy's impact on the econ

86 Whether these alterations in ART-treated HIV subjects occur in vitro in HIV-infected

87 ative risk of SIV-induced TB reactivation in ART-treated macaques in the early phase of treatment.

88 Data included ART use and anti-tuberculosis medications grouped accord

89 to access uninterrupted treatment, including ART.

90 lence of undiagnosed HIV infection, increase ART use among all people living with HIV, and make subst

91 Thus, we studied 4 simian/HIV-infected, ART-suppressed rhesus macaques infused with virus-specif

92 Using an in vitro HIV-infected, ART-treated MDM model, we show that ZL0580 also induces

93 ses can be detected in children who initiate ART after 2.3 months of age and are probably, as in adul

94 ortion of those diagnosed who ever initiated ART; and proportion of those ever treated who achieved v

95 among the 835 participants who had initiated ART was 1.9 per 100 person-years (95% CI 0.9-3.9).

96 .1%, 95% CI 53.7-60.6) individuals initiated ART within 1 day of linkage, 589 (73.7%, 70.6-76.7) of 7

97 ences were from three children who initiated ART after 2.3 months of age, one of whom had two identic

98 could be detected in children who initiated ART after 2.3 months of age.

99 n among adults living with HIV who initiated ART and had serum 25-hydroxyvitamin D concentrations of

100 ith HIV aged 15 years or older who initiated ART at a programme site were eligible for analysis.

101 were detected in four children who initiated ART before 2.3 months of age.

102 tive cohort study included adults initiating ART at facilities providing universal ART since January

103 LWH with severe immunosuppression initiating ART, baseline low BMI and hemoglobin and high CRP and D-

104 itive adults >=18 years old newly initiating ART in 4 Zambian provinces (Eastern, Lusaka, Southern, a

105 e previous concerns, participants initiating ART with CD4 counts >=500 cells/uL had very good virolog

106 rying clinic sizes (10-50 patient initiating ART per month).

107 d gestation of at least 28 weeks, initiating ART in third trimester.

108 Within a cohort of women initiating ART during pregnancy in Cape Town, South Africa, we comp

109 ated to initiating (including re-initiating) ART in the hospital and its association with linkage to

110 D group) were compared to women on non-INSTI ART (STAY group).

111 te to viral rebound in some PWH interrupting ART.IMPORTANCE To cure HIV, we likely need to target the

112 d in some people with HIV (PWH) interrupting ART.

113 We investigated ART failure, drug resistance, and early mortality among

114 d HIV-seropositive, qualified for first-line ART, planned to reside in the area for more than 1 year,

115 centage points, and switching to second-line ART by 1 percentage point compared with standard of care

116 ved among candidates screened for third-line ART in LMIC, ranging from no resistance to resistance to

117 Food insecurity was associated with lower ART concentrations in hair, suggesting that food insecur

118 months controlling for enrollment measures, ART group, age, and RTI using generalized estimating equ

119 re, 35 (3.0%) were CrAg positive with median ART duration of 41 months (interquartile range, 10-84 mo

120 2 HIV-infected participants receiving modern ART to determine the kinetics of plasma viral rebound fo

121 cant clinical concern in carefully monitored ART suppressed HIV-positive organ recipients.

122 ission (0.3-86.1/100PY, by HIV RNA), monthly ART costs ($2,290-$3,780), and HIV per-screen costs ($38

123 In blind testing, no ART was detected in 300 infection-nonreactive donor samp

124 equation and generalized linear models (non-ART group pVL and hemoglobin) in as-treated analyses.

125 or those who were CrAg positive, we obtained ART history, meningitis occurrence, and 6-month survival

126 group had virological failure at month 12 of ART (95% CI 6.0-11.7) compared with 39 (9.7%) of 402 (7.

127 In the absence of ART, plasma virus rebounded to 10(3) vRNA copies/ml by d

128 ible studies investigated the association of ART, CD4+ count, or HIV PVL on histology-confirmed CIN2+

129 HIV-related factors, and the composition of ART regimens as contributors.

130 rica and Uganda, community-based delivery of ART significantly increased viral suppression compared w

131 tion during the relatively short duration of ART administered in this study.

132 randomised trial to determine the effect of ART-only versus ART plus kick and kill on markers of the

133 terval [CI], 11.5% to 20.0%) had evidence of ART.

134 ent recrudescences and protect the future of ART-based combination therapies.

135 To understand the impact of ART on the gut microbiota, we used the rhesus macaque mo

136 In contrast, the influence of ART on subclinical atherosclerosis is not clear.

137 /mm3 thereafter) to the 'Early Initiation of ART for All' (EAAA) intervention at one of seven timepoi

138 r well-established nonhuman primate model of ART-suppressed HIV-1 infection, we tested strategies to

139 nts (cholecalciferol) for the first month of ART followed by daily 2000 IU vitamin D(3) supplements o

140 Within 6 months of ART, 97 (19.2%) participants developed IRIS and 31 (6.5%

141 IV infection and at different time points of ART.

142 f Tregs, the side effects in the presence of ART prevent their clinical use and call for different Tr

143 eurons were less affected in the presence of ART.

144 Although an interruption in the supply of ART drugs would have the largest impact of any potential

145 of HIV DNA are determined around the time of ART initiation in individuals treated during PHI.

146 V RNA expression in the blood and tissues of ART-suppressed bone-marrow-liver-thymus (BLT) humanized

147 ght gain is ubiquitous in clinical trials of ART initiation and is multifactorial in nature, with dem

148 Scale-up of ART over the last decade has already contributed to subs

149 fic and sex-specific gaps in the scale-up of ART, to estimate the historical and future effect of att

150 ual viremia (pre-ART vs after 24-48 weeks of ART: 19% vs 94%, P < .001).

151 any immunological variables after 1 year of ART.

152 On ART, PTCs had significantly lower levels of residual pla

153 al blood samples from 400 HIV-1(+) adults on ART from several diverse cohorts, representing a robust

154 n of people living with HIV diagnosed and on ART; proportion of people living with HIV on ART with vi

155 erinflamed profile and increases in cfPWV on ART.

156 and decreases in lung function are common on ART, relate to greater ART-mediated CD4 T-cell restorati

157 control of HIV-1 infection (controllers) on ART, included because controllers have strong HIV-1-spec

158 ART; proportion of people living with HIV on ART with viral suppression; and proportion of HIV-negati

159 living with HIV (HIV+) who were initiated on ART before 3 years of age in a prior clinical trial comp

160 lity, 1315 people living with HIV and not on ART with detectable viral load at baseline were randomly

161 infection, 2% of proviruses that persist on ART are genetically intact by sequence analysis.

162 the size of the residual latent reservoir on ART.

163 6.0), and viral load suppression of those on ART increased from 88.7% (83.6-93.8) to 91.3% (88.6-94.1

164 Participants' median time on ART prior to ATI was 3 years, and ATI lasted a median of

165 cells and are often maintained over time on ART.

166 PHIV were on ART, with HIV-1 RNA levels <=400 copies/mL.

167 people living with HIV (91% of 1353) were on ART; 1166 people living with HIV (88% of 1321 with avail

168 HIV infection, we hypothesized that women on ART would have a lower frequency of latent HIV compared

169 d for eligibility (HIV+, age >= 14 years, on ART >6 months, not acutely ill, CD4 count not <200 cells

170 Using sampling-based optimization, ART provides a set of recommended strains to be built in

171 PFS 50%, 32 to 67; n=59) and etoposide plus ART (20%, 6 to 33; n=59), and -20% (-33% to -7%) for the

172 wing superiority to both oral etoposide plus ART and bleomycin and vincristine plus ART, supporting i

173 The etoposide plus ART arm also closed due to inferiority in March, 2016, f

174 o -7%) for the comparison of paclitaxel plus ART (64%, 55 to 73; n=138) and bleomycin and vincristine

175 to -8) for the comparison of paclitaxel plus ART (week 48 PFS 50%, 32 to 67; n=59) and etoposide plus

176 rvention was not shown, with paclitaxel plus ART showing superiority to both oral etoposide plus ART

177 3; n=138) and bleomycin and vincristine plus ART (44%, 35 to 53; n=132).

178 plus ART and bleomycin and vincristine plus ART, supporting its use in treating advanced AIDS-associ

179 ntly later (median of 66 versus 42 days post-ART interruption, P < 0.01) and reached lower levels (me

180 erial stiffness 2, 12, 24, and 42 weeks post-ART initiation.

181 preserved Th17 homeostasis, including at pre-ART, are the main features associated with sustained vir

182 The prevalence of pre-ART DRMs was 10% in cases and 5% in controls (adjusted o

183 s; however the relative contributions of pre-ART drug resistance mutations (DRMs) vs nonadherence in

184 uals with undetectable residual viremia (pre-ART vs after 24-48 weeks of ART: 19% vs 94%, P < .001).

185 tions to expand donor options and to prevent ART interruptions for patients with HIV in need of alloB

186 Prolonged ART may restore the richness of the microbiota closer to

187 disease with LPs and blood cultures, prompt ART initiation, and more intensive antifungals may reduc

188 rrent HIV treatment guidelines urging prompt ART initiation after HIV diagnosis.

189 e rapid ART introduction and 800 after rapid ART introduction.

190 adults linked to study clinics before rapid ART introduction and 800 after rapid ART introduction.

191 gibility policies (Treat All) improved rapid ART initiation after care enrollment among 10-14-year-ol

192 During the rapid ART period, 457 (57.1%, 95% CI 53.7-60.6) individuals in

193 idence rates in HIV-positive women receiving ART were higher than those in untreated HIV-positive wom

194 Failure to reinitiate ART within 18 months was common in this sample.

195 ad, lack of retention in care in the on-site ART programme) at 6 months.

196 PHIVs were on stable ART with HIV-1 RNA <400 copies/mL.

197 p, 835 (86%) of 975 participants had started ART.

198 macaques (RMs), defined as PTCs, who started ART 8 weeks postinfection, continued ART for >7 months,

199 In eight children who started ART at a median age of 5.4 months (range, 2.0 to 11.1 mo

200 Thirty participants who started ART during acute HIV infection underwent CNS assessments

201 Findings suggest starting ART in the hospital is beneficial for increasing linkage

202 y; n = 2 with rebound viremia after stopping ART), who provided serial blood samples before death and

203 We studied ART-naive participants from the ADVANCE study randomized

204 insecurity may be associated with suboptimal ART adherence and/or drug absorption.

205 of the HIV DNA reservoir during suppressive ART, even when ART is initiated during the earliest phas

206 ain HIV tissue reservoirs during suppressive ART, suggesting future cure strategies should study inte

207 useful for screening children on suppressive ART for enrolment into therapeutic vaccine trials and ot

208 ency syndrome (AIDS) or death on suppressive ART were calculated by PIR status.

209 The ability of malaria parasites to survive ART monotherapy may relate to an innate growth bistabili

210 ecies with alternative reproductive tactics (ARTs) exhibit robust, consistent differences in behavior

211 t 26, 2015, and Sept 19, 2017, 786 had taken ART for at least 6 months.

212 who were HIV-positive and not already taking ART were offered universal HIV-treatment and same-day AR

213 Persons who are HIV positive and taking ART and persons taking PrEP to prevent HIV infection are

214 rts of tenofovir toxicity in patients taking ART for HIV cannot be explained solely on the basis of o

215 Men living with HIV with urethritis taking ART >=12 weeks were enrolled at a sexually transmitted i

216 eful for assisted reproductive technologies (ARTs), as it can allow specific selection of sperm cells

217 Little is known about effect of long-term ART on gut microbiome in HIV-infected children.

218 program of individuals undergoing long-term ART.

219 ent analysis, among patients enrolled in the ART (n=3102), we excluded those who did not undergo surg

220 ity of gut microbiome composition, while the ART group appeared to recover towards the diversity leve

221 perfect adherence to antiretroviral therapy (ART) (OR, 2.8; P < .001), and depression (OR, 1.9; P < .

222 (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased

223 Although antiretroviral therapy (ART) can control the virus, it does not provide cure.

224 mmune restoration on antiretroviral therapy (ART) can drive inflammation in people living with human

225 of data on access to antiretroviral therapy (ART) care and social or clinical context at the destinat

226 In adults starting antiretroviral therapy (ART) during acute infection, 2% of proviruses that persi

227 fering same-day (SD) antiretroviral therapy (ART) during home-based human immunodeficiency virus test

228 A key component of antiretroviral therapy (ART) for HIV patients is the nucleoside reverse transcri

229 The use of antiretroviral therapy (ART) has remarkably decreased the morbidity associated w

230 Advances in antiretroviral therapy (ART) have made it possible for persons with human immuno

231 d after cessation of antiretroviral therapy (ART) in 18 acutely treated and durably suppressed indivi

232 Despite the use of antiretroviral therapy (ART) in HIV-1 infected mothers approximately 5% of new H

233 te initiation of HIV antiretroviral therapy (ART) in pregnancy is associated with not achieving viral

234 n and adolescents on antiretroviral therapy (ART) in sub-Saharan Africa.

235 Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children limits the size

236 0%), linkage-to-care/antiretroviral therapy (ART) initiation (76%), HIV transmission (0.3-86.1/100PY,

237 oad (VL) early after antiretroviral therapy (ART) initiation appears frequently in pregnant and postp

238 V) seroconversion to antiretroviral therapy (ART) initiation during an era of expanding HIV testing a

239 effect of very early antiretroviral therapy (ART) initiation on the rate of recrudescence and the vir

240 up to 48 weeks post-antiretroviral therapy (ART) initiation.

241 (IRIS) and death at antiretroviral therapy (ART) initiation.

242 itive individuals on antiretroviral therapy (ART) is an important milestone for efforts to cure HIV-1

243 and women receiving antiretroviral therapy (ART) is incompletely characterized.

244 sessed the effect of antiretroviral therapy (ART) on HIV suppression, immune activation, and quality

245 The effect of antiretroviral therapy (ART) on the natural history of anal high-risk HPV and an

246 nitiated suppressive antiretroviral therapy (ART) regimens in infancy, HIV-1-specific antibody concen

247 ants receiving older antiretroviral therapy (ART) regimens with infrequent virologic monitoring.

248 Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and c

249 each nurses, and (2) antiretroviral therapy (ART) via community pharmacies.

250 Antiretroviral therapy (ART) was associated with significantly better T scores o

251 375H.dCT, and triple antiretroviral therapy (ART) was initiated after 16 weeks.

252 ents (94.3%) were on antiretroviral therapy (ART), 88.7% had HIV virologic suppression, and 80.8% had

253 HIV testing, earlier antiretroviral therapy (ART), and strengthened male circumcision services, and 1

254 e global scale-up of antiretroviral therapy (ART), incarcerated people have not benefited equally fro

255 Despite antiretroviral therapy (ART), low-level persistent HIV replication in these rese

256 We analyzed antiretroviral therapy (ART)-eligible adults newly linking to care at 64 clinics

257 egative (HIV(-)) and antiretroviral therapy (ART)-suppressed HIV-positive (HIV(+)) individuals.

258 of plasma viremia in antiretroviral therapy (ART)-treated simian immunodeficiency virus-infected rhes

259 ected individuals on antiretroviral therapy (ART).

260 al persistence under antiretroviral therapy (ART).

261 istence in people on antiretroviral therapy (ART).

262 le to initiate early antiretroviral therapy (ART).

263 the effective use of antiretroviral therapy (ART).

264 sts despite years of antiretroviral therapy (ART).

265 to 40 years old) on antiretroviral therapy (ART).

266 opardizes success of antiretroviral therapy (ART).

267 ting efavirenz-based antiretroviral therapy (ART).

268 y infections despite antiretroviral therapy (ART).

269 eight individuals on antiretroviral therapy (ART).

270 e global scale-up of antiretroviral therapy (ART).

271 es of treatment with antiretroviral therapy (ART).

272 iduals during combination antiviral therapy (ART).

273 Data from three ART programmes were linked with routine medical records

274 40 copies/mL) despite reported adherence to ART and the absence of drug resistance to the current AR

275 While the time from diagnosis to ART initiation decreased to 0.2 years, the time from ser

276 06-2017 who switched to or added an INSTI to ART (SWAD group) were compared to women on non-INSTI ART

277 RNA and viral DNA in these animals prior to ART initiation, during ART suppression, and following vi

278 ates over time since linkage with respect to ART initiation, retention in care, transfers, and mortal

279 lementation of the new model reduced time to ART initiation from 264 to 23 days and increased communi

280 line demographic characteristics and time to ART initiation using Cox proportional hazard models, and

281 ic and clinical variables, including time to ART initiation, and the proportion of participants with

282 whether universal antiretroviral treatment (ART) eligibility policies (Treat All) improved rapid ART

283 HIV infection and antiretroviral treatment (ART) have been associated with increased rates of preter

284 d persons starting antiretroviral treatment (ART) in a high tuberculosis endemic area is described.

285 (CLHIV) receiving antiretroviral treatment (ART) in resource limited settings are susceptible to hig

286 Uptake of antiretroviral treatment (ART) is expanding rapidly in low- and middle-income coun

287 system based on the area of residual tumor (ART).

288 iating ART at facilities providing universal ART since January 2014.

289 itoring and ART refills through mobile vans; ART initiation at the clinic followed by mobile van moni

290 l to determine the effect of ART-only versus ART plus kick and kill on markers of the HIV reservoir.

291 Among 171 viremic ART-experienced participants, NNRTI mutation prevalence

292 e 34 years [interquartile range 28-41]) were ART-eligible at enrollment.

293 rs, inclusive) with HIV-1 infection who were ART naive.

294 reservoir during suppressive ART, even when ART is initiated during the earliest phases of HIV infec

295 While ART drugs are shown to be effective in attenuating HIV r

296 There was no association with ART initiation in the hospital and retention in HIV care

297 roach that could be used in combination with ART to suppress residual HIV replication and/or latent H

298 ife-threatening viral rebound can occur with ART interruption.

299 five SHIV(SF162P3)-infected RMs treated with ART for 12 months and with plasma viremia consistently b

300 mmune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than durin